重组人血管内皮抑制素注射液联合化疗方案治疗晚期非小细胞肺癌上的疗效及安全性  

The Efficacy and Safety of Endostar Combined With Chemotherapy in Treatment of Advanced Non-small Cell Lung Cancer

作　　者：刘元华[1] 

机构地区：[1]江苏省肿瘤医院肿瘤内科,南京210009

出　　处：《中国继续医学教育》2015年第22期121-122,共2页China Continuing Medical Education

摘　　要：目的探讨重组人血管内皮抑制素注射液联合化疗方案治疗晚期非小细胞肺癌的临床疗效和安全性。方法选取2010年6月~2014年6月来我院就诊的100例晚期非小细胞肺癌患者为研究对象,按照患者临床治疗方法分为两组,观察组和对照组各50例患者,观察组采用化疗结合重组人血管内皮抑制素注射液治疗方式,而对照组患者应用单纯化疗方式治疗,对比分析两组患者的临床疗效以及受益率,结果观察组患者的临床有效率及临床受益率高于对照组患者,两组患者结果差异有统计学意义（P〈0.05）;而两组患者的不良反应差异无统计学意义（P〉0.05）。结论重组人血管内皮抑制素注射液联合化疗方案治疗晚期非小细胞肺癌的治疗方法安全有效,有效地抑制了肿瘤的恶化和进一步的发展,临床应用价值较高。Objective To investigate the grace of chemotherapy in the treatment of clinical efficacy and safety of advanced on non-small cell lung cancer. Methods 100 patients with advanced non-small cell lung cancer patients were researched in June 2010 to June 2014 in our hospital, according to the clinical aeatment of patients divided into two groups, the observation group and the control group, 50 patients were observed chemotherapy combined with endostatin group treatment, while the control group patients chemotherapy treatment approach, comparative analysis of the two groups of patients with clinical efficacy and benefit rate. Results Effective clinical and clinical benefit rate of observer group is significantly higher than control patients, the results of two groups of patients were significantly different （P〈0.05）. The adverse reactions of the two groups were similar, no significant difference in the results of the two groups of patients, no statistically significant （/〉〉0.05）. Conclusion Endostar combination chemotherapy treatments for advanced non-small cell lung cancer is safe and effective, effectively inhibit the deterioration of the tumor and further development, higher clinical value.

关 键 词：重组人血管内皮抑制素注射液 晚期非小细胞肺癌 临床疗效 

分 类 号：R734[医药卫生—肿瘤]